This review describes trials evaluating the monoclonal antibody pembrolizumab (an immunotherapy that blocks the interaction between PD-L1/PD-L2) as first-line therapy for advanced non-small-cell lung cancer.
In this research article from the Journal of Comparative Effectiveness Research find out about the characteristics and treatment patterns among US patients with hairy cell leukemia.
This paper drives home the point that targeted and contextualized interventions are key to improving the quality of life of cancer survivors.
Find out about the chemical and physical features of nanoparticulate systems that can be tuned to address the anticancer immune response and recent key examples of the exploited strategies, ranging from nanovaccines to NPs revising the tumor immunosuppressive microenvironment, up to immunotherapeutic multimodal NPs.
Among other criteria, in this research article from Future Science OA, the authors validated the Gynecological Cancer Intergroup CA125 progression criteria in an ovarian cancer population regarding sensitivity, specificity, positive predictive value and negative predictive value.
In this editorial from Future Oncology the authors explore tumor biology, host biology and patient’s quality of life in respect to circumvent hesitancy between CDK4/6 and mTOR inhibitors in second-line treatment of HR+, erb2- metastatic breast cancer.
This article first reviews the brief achievements in using albendazole to treat parasites and cancers, and summarizes the basic mechanisms of action of albendazole.
Discover preliminary data for a new assay workflow to detect the presence of PD-L1 and PD-L2 on the surface of tumor cells that have broken away from the tumor and entered the blood in this research article from Future Science OA.
How could the epigenome serve as a promising therapeutic target in reversing cancer-associated muscle catabolism? Find out in this commentary article from Epigenomics.